USE Long-Term Celecoxib

USE Long-Term Celecoxib (buy Celebrex) and Other NSAIDs Bound on Disadvantage Kidney Effects

In November 2, 2007, FED.UPR.LEK.PREPARATOV And PROD.PITANIYA approved safety, marking corrections for celecoxib capsules (Celebrex; GD Searle, LLC) TO report on risk for disadvantage kidney effect on patient, getting processing with celecoxib and other nonsteroidal inflammatory medicine (NSAIDs).

Either as other NSAIDs, long-term use celecoxib can conduct to kidney necrosis, kidney insufficiency, quiping kidney failure, and other kidney damages. On patient for which kidney prostaglandins to have compensating role in usages kidney perfusion, NSAIDs can cause the dose-hung reduction on prostaglandin formation and, a second time, kidney blood flow, which can bring about open kidney decompensation.

The Patients with spoiled kidney function, heart failure, or liver dysfunction; the elderly patients; and that taking the diuretics, angiotensin converting inhibitor of the enzyme (the ACE), and angiotensin antagonists of the receptor II - in the most great risk for this reactions. The Cessation NSAID therapy usually follows reconstruction in condition pretreatment.

According to studies also remind to NSAIDs could reduce the effect antihypertensive inhibitor of the ACE and angiotensin antagonist of the receptor II. This interaction must be considered when concomitant therapy with these agent is given.

Celecoxib is Specified to relieve the signs and osteoarthritis, ankylosing спондилит, and rheumatoid arthritis. This can is also used for governing the pang in adult, processing primary dysmenorrhea, and reduction in row colorectal polyp in household adenomatous polyposis.

Lopinavir/Ritonavir MEDICINE (Kaletra) Interaction With Rifampin

In October 26, 2007, approved safety, marking corrections for lopinavir/ritonavir tablet and spoken decision (Kaletra; Abbott) To be warned contraindications in concomitant therapy with the other agent.

Lopinavir/ritonavir can Not coadministered medicine, which much hung from cytochrome P450 isoenzyme 3A (CYP3A) for clearance and for which lifted concentration are bound serious or life-threat reaction, or both.

Also, use the concomitant lopinavir/ritonavir contraindicated strong CYP3A inducers because of significant reduction in lopinavir to concentrations, which can be bound loss virologic answer and potential resistance and cross-resistances.

antimycobacterial rifampin, Herbal product St. John wort, and 3 hydroxy metil-glutaryl-CoA reductase inhibitors lovastatin and simvastatin is added to list medicine in sections of the contraindications of the safe label lopinavir.

Use the Concomitant rifampin or St. John wort with lopinavir/ritonavir can conduct to loss virologic answer and possible resistance on lopinavir or protease inhibitors as class; rifampin can also cause the resistance other coadministered antiretroviral agent. Use the Concomitant lovastatin or simvastatin is bound in risk for myopathy, including rhabdomyolysis and like contraindicated.

Raised Ritonavir lopinavir in combinations with other antiretroviral agent is specified for processing the infections HIV-1.